✦ LIBER ✦

Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group

✍ Scribed by Giessen, C.; Graeven, U.; Laubender, R. P.; Modest, D. P.; Schulz, C.; Porschen, R.; Schmiegel, W.; Reinacher-Schick, A.; Hegewisch-Becker, S.; Stintzing, S.; Heinemann, V.

Book ID: 121656499
Publisher: Oxford University Press
Year: 2013
Tongue: English
Weight: 98 KB
Volume: 24
Category: Article
ISSN: 0923-7534
DOI: 10.1093/annonc/mdt402

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Analysis for Prognostic Factors of 60-da

Analysis for Prognostic Factors of 60-day Mortality: Evaluation of an Irinotecan-Based Phase III Trial Performed in the First-Line Treatment of Metastatic Colorectal Cancer

✍ Clemens Giessen; Sebastian Stintzing; Ruediger Paul Laubender; Donna Pauler Anke 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 295 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306

✍ Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Jage 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 225 KB

6137 POSTER Biological Analysis of Phase

6137 POSTER Biological Analysis of Phase II Study Evaluating the Activity of Cetuximab Combined to Oxaliplatin and Fluoropirimidine (TEGAFOX-E) as First Line Treatment in Metastatic Colorectal Cancer (mCRC) Pts by the Italian Trials in Medical Oncology (I.T.M.O.) Group

✍ Bartolomeo, M. Pi; Dotti, K.F.; Pietrantonio, F.; Perrone, F.; Martinetti, A.; P 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 41 KB

6096 POSTER FOLFOXIRI (Irinotecan, Oxali

6096 POSTER FOLFOXIRI (Irinotecan, Oxaliplatin, and Infusional 5FU/LV) in Combination With Panitumumab (P) in the First-line Treatment of Metastatic Colorectal Cancer (mCRC) Patients (pts) Selected for KRAS, BRAF, NRas and HRas Mutational Status – a Phase II Study by the G.O.N.O. Group

✍ Fornaro, L.; Loupakis, F.; Lonardi, S.; Masi, G.; Salvatore, L.; Cremolini, C.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 49 KB